$ANGO

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

AngioDynamics reported Q1 fiscal 2027 revenue of $80.9M, up 6.9% YoY. Med Tech revenue grew 13.2% to $39.9M, while Med Device revenue rose 1.4% to $41M. Gross margin expanded to 59.4%. The company reported a GAAP net loss of $7.1M, improving from last year. Adjusted EBITDA increased to $5M. AngioDynamics reiterated its full-year revenue guidance of $336M to $341M.

Canaccord Genuity kept a Buy rating on AngioDynamics with a $20 price target, suggesting a 78.1% upside. The company reported $80.9M revenue, up 6.9% YoY, and expects positive cash flow for the fiscal year.

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NEWS RELEASE Investor Contact: Stephen Trowbridge Executive Vice President & CFO 518-795-1408 strowbridge@angiodynamics.com Media Contact: Saleem Cheeks Vice President, Communications 518-795-1174 scheeks@angiodynamics.com AngioDynamics Announces Appointment of Eric

AngioDynamics (ANGO) announced a $50,000-$750,000 research grant for Jacobi Hospital to study imaging biomarkers in pulmonary embolism patients, aiming to predict treatment success. The study is supported by The PERT Consortium and focuses on CT pulmonary angiography radiomics.

AngioDynamics (ANGO) will report Q1'26 earnings on October 8. Analysts expect revenue of 80.51M USD and EPS of (0.11) USD.

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.